openPR Logo
Press release

Duchenne Muscular Dystrophy - Pipeline Review, H2 2017

10-27-2017 01:15 PM CET | Health & Medicine

Press release from: ReportsWorldwide

Duchenne Muscular Dystrophy - Pipeline Review, H2 2017

Duchenne Muscular Dystrophy - Pipeline Review, H2 2017

ReportsWorldwide has announced the addition of a new report title Duchenne Muscular Dystrophy - Pipeline Review, H2 2017 to its growing collection of premium market research reports.

Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Duchenne Muscular Dystrophy - Pipeline Review, H2 2017, provides an overview of the Duchenne Muscular Dystrophy (Genetic Disorders) pipeline landscape.

Duchenne muscular dystrophy is a condition which causes muscle weakness. DMD is an X-linked disorder. The gene for DMD is present on the X chromosome. It codes for a protein named dystrophin. Dystrophin is essential for providing structural support inside muscle cells. Symptoms usually appear before age 6 and may appear as early as infancy. They include fatigue, learning difficulties, intellectual disability, muscle weakness and progressive difficulty walking.

Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Duchenne Muscular Dystrophy - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Duchenne Muscular Dystrophy (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Duchenne Muscular Dystrophy (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Duchenne Muscular Dystrophy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 3, 4, 12, 11, 2, 53 and 15 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 2, 8 and 1 molecules, respectively.

Duchenne Muscular Dystrophy (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

To Enquire about this Report please visit @ https://www.reportsworldwide.com/enquiry?report_id=41741

Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Duchenne Muscular Dystrophy (Genetic Disorders).
- The pipeline guide reviews pipeline therapeutics for Duchenne Muscular Dystrophy (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Duchenne Muscular Dystrophy (Genetic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Duchenne Muscular Dystrophy (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Duchenne Muscular Dystrophy (Genetic Disorders)

Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Duchenne Muscular Dystrophy (Genetic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Duchenne Muscular Dystrophy (Genetic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

To view a detailed description and Table of Contents please visit: https://www.reportsworldwide.com/report/duchenne-muscular-dystrophy-pipeline-review-h2-2017

ReportsWorldwide.com is a leading provider of global market intelligence reports and services. With research reports from top publishers, consulting and advisory firms, ReportsWorldwide.com offers instant online access to a growing database of expert insights on global industries, companies, products, geographies and trends. Moreover, ReportsWorldwide's Research Associates have in-depth knowledge of the reports and services on offer and are ready to provide assistance.

Press Contact:
Abigail Crasto
Senior Vice President
101, Arch Street
Boston, MA 02110
US
Phone +1 (617) 398-4994
Fax +1 (617) 398-4995
abigail@reportsworldwide.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Duchenne Muscular Dystrophy - Pipeline Review, H2 2017 here

News-ID: 790322 • Views:

More Releases from ReportsWorldwide

World Deep Brain Stimulation Market Top Segments, Key Players Revenue, Growth Ra …
The World Deep Brain Stimulation Market is estimated to represent a global market of USD 751.8 million by 2017 with growth rate of 18.2%. Deep brain stimulation (DBS) procedure is primarily used for the treatment of neuropsychiatric disorders such as mood disorder, dementia, anxiety and others. The procedure involve the use of neurotransmitter (brain pacemaker) that enables to transmit electric impulses to the specific target of brain cells. Increasing incidence
New report explores the Gene Editing Market : Ushering The Next Breakthrough in Regenerative Medicine
New report explores the Gene Editing Market : Ushering The Next Breakthrough in …
Boston, MA ReportsWorldwide has announced the addition of a new report title Gene Editing The Next Breakthrough in Regenerative Medicine to its growing collection of premium market research reports. Genome editing is a type of genetic engineering in which DNA is replaced, inserted or deleted in a living organism's ggenome using engineered molecular scissors. Believed to be one of the great biotechnology breakthroughs, gene editing is a powerful tool in pharmaceutical research that
Global In-Building Wireless BTSController-based Small Cells Market Analysis and Forecast, 2017-2021
Global In-Building Wireless BTSController-based Small Cells Market Analysis and …
Boston, MA ReportsWorldwide has announced the addition of a new report title Global In-Building Wireless BTSController-based Small Cells Market Analysis and Forecast, 2017-2021 to its growing collection of premium market research reports. This report covers the leading in-building wireless enterprise BTS/controller-based small cells network equipment manufacturers: • CommScope/Airvana • Comba Telecom • Ericsson • Huawei Technologies • Nokia • SpiderCloud • ZTE Corporation This report covers the global market share for 2016 shipments as well as a forecast for 2017-2021. To view a detailed description and Table of

More Releases for Duchenne

Duchenne Muscular Dystrophy (DMD) Drugs Market Report
As per the research conducted by GME, the Duchenne Muscular Dystrophy (DMD) Drugs Market will grow with a CAGR value of 41.3 percent by 2026. The global market for Duchenne muscular dystrophy is foreseen to grow due to accelerated research and development activities, expanded patient awareness for effective treatments, and the launch of new medications Moreover, the disease's increasing prominence is likely to drive the global duchenne muscular dystrophy market
Global Duchenne Muscular Dystrophy Market Research Report 2015-2025
About the Global Duchenne Muscular Dystrophy Market Research Report 2015-2025: Global Global Duchenne Muscular Dystrophy Market Research Report 2015-2025 2020 Research Report is divided into various key segments like device type, material, applications, and end users. The report is thoroughly analyzed and studied by the researchers to offer deep insights on each of these segments with statistics. This information is beneficial for the manufacturers in the industry to plan their policies
Global Duchenne Muscular Dystrophy Therapeutics Market Productions, Statistics 2 …
Qyresearchreports include new market research report "Global Duchenne Muscular Dystrophy Therapeutics Market Size, Status and Forecast 2022" to its huge collection of research reports. The general market for Duchenne Muscular Dystrophy Therapeutics has been analysed on various points of view that are practically present in the scenario, and have affected the market situation to the large extent. The report also presents exceptional experience and data identified with global Duchenne Muscular Dystrophy
Duchenne Muscular Dystrophy (DMD) Treatment Market - Global Industry Insights, T …
Duchenne muscular dystrophy (DMD) is a genetic disorder characterized by progressive muscle degeneration and weakness. DMD is caused due to alteration in gene sequence coding for dystrophin proterin, which is present the muscle. It is a rare muscle disease which majorly affects males. The symptoms includes intellectual disability, muscle weakness and, difficulty in walking and breathing. Congestive heart failure, mental impairment, pneumonia or respiratory failure are some of the
Duchenne Muscular Dystrophy (DMD) Market Forecast Research Reports Offers Key In …
Duchenne muscular dystrophy (DMD) is a genetic disorder characterized by muscle degeneration and weakness. Duchenne muscular dystrophy (DMD) cause due to lack of protein known as “dystrophin” which causes muscles deterioration and break down, leads to difficulty in walking and general mobility. DMD is a one of the most progressive childhood neuromuscular disorders. It affects mostly boys, but occasionally girls are affected. According to Muscular Dystrophy Australia, in 2016, Duchenne
Duchenne Muscular Dystrophy - Pipeline Review, H2 Pharmaceutical Research Report …
Market Research Hub (MRH) has recently publicized a new study to its vast repository, which is titled as “Duchenne Muscular Dystrophy - Pipeline Review, H2 2017”. Duchenne muscular dystrophy is a condition which causes muscle weakness. DMD is an X-linked disorder. The gene for DMD is present on the X chromosome. Request For Sample Report: http://www.marketresearchhub.com/enquiry.php?type=S&repid=1305512 It codes for a protein named dystrophin. Dystrophin is essential for providing structural support inside muscle cells.